D. Mark Durcan, who serves as a director at Cencora, Inc. (NYSE:COR), executed an open-market purchase of the company's common stock on May 28, 2026. The transaction involved acquiring 4,000 shares of Cencora common stock, valued at $266.26 per share, totaling a commitment of $1,065,040.
Following this specific acquisition, Mr. Durcan's direct holdings in Cencora common stock increased to 27,767 shares. This insider buying activity takes place as the healthcare company, which possesses a market capitalization estimated at $52 billion, is trading below its InvestingPro Fair Value.
Market Context and Valuation Perception
The purchase by Mr. Durcan occurs against a backdrop of mixed market signals for Cencora. While the stock has experienced a decline of 21% year-to-date, the company maintains a long history, having raised dividends for 21 consecutive years. The fact that the company is trading below its calculated InvestingPro Fair Value suggests potential valuation upside according to certain metrics.
Recent Financial Performance and Analyst Reactions
In separate company news, Cencora Inc. released its second-quarter earnings report for fiscal year 2026. The reported figures indicated a shortfall compared to market projections. Specifically, the company announced an earnings per share (EPS) of $4.75, which was lower than the anticipated $4.83. Furthermore, revenue reached $78.4 billion, falling short of the forecasted $80.97 billion.
Notwithstanding these quarterly results, analyst coverage remained constructive. TD Cowen reaffirmed a Buy rating for Cencora, setting and maintaining a price target of $400.00. The firm cited its confidence in Cencora’s generics strategy as the basis for this positive outlook. However, alongside the buy recommendation, Cencora did make adjustments to its forward guidance.
The company lowered its U.S. healthcare revenue guidance downward, although it took the step of keeping its U.S. healthcare adjusted operating income guidance unchanged.
Executive Leadership Changes
In terms of corporate structure, Cencora also announced a key executive transition. Eva C. Boratto is slated to join the company as Executive Vice President and Chief Financial Officer, effective June 29, 2026. Ms. Boratto brings prior experience serving as CFO at Bath & Body Works Inc.
She will be replacing James F. Cleary. Mr. Cleary is retiring but has committed to remaining in an advisory capacity through the end of 2026. These leadership developments were announced concurrently with Cencora's reaffirmation of its overall fiscal 2026 guidance.
Investment Considerations
For investors seeking deeper analysis into Cencora’s valuation and potential growth trajectories, comprehensive reports are available. These resources cover COR and over 1,400 additional US equities.